Efficacy in Japanese adults with growth hormone deficiency receiving weekly somapacitan or daily growth hormone: results from phase 3 REAL 1 trial [PDF]
Frontiers in EndocrinologyIntroductionSomapacitan is a long-acting growth hormone (GH) derivative approved for once-weekly treatment of adult GH deficiency (AGHD). This study aimed to evaluate the efficacy and safety of somapacitan and daily GH in Japanese individuals with AGHD ...
Fumio Otsuka +5 more
doaj +2 more sources
Comparison of efficacy and safety between long-acting growth hormone and short-acting growth hormone in isolated growth hormone deficiency: a systematic review and meta-analysis of 16 randomized controlled trials involving 2,435 pediatric patients [PDF]
Frontiers in PediatricsObjectiveTo comprehensively compare the efficacy and safety of long-acting human growth hormone (LAGH) preparations with conventional short-acting daily growth hormone (SA-GH) in children with isolated growth hormone deficiency (GHD), and explore ...
Zhen-Zhen Shen +4 more
doaj +2 more sources
Usability and Preference Evaluation of the Somapacitan Pen-Injector and Lonapegsomatropin Autoinjector: Results of a US-Based Simulated-Use Study with Adolescent Patients and Caregivers [PDF]
Patient Preference and AdherenceJohan Medina,1 Gitte Ter-Borch,2 Nicky Kelepouris,3 Sophie Hamilton,3 Maya Gonczi,4 Jørgen Vinsløv Hansen,5 Shahid Akhtar1 1Medical & Science, Devices & Digital Health, Novo Nordisk A/S, Søborg, Denmark; 2Usability Engineering, Devices and Delivery ...
Medina J +6 more
doaj +2 more sources
New directions in growth hormone treatment in children [PDF]
Pediatric Endocrinology, Diabetes and MetabolismThis paper reviews clinical-trial evidence on the use of long-acting growth hormone (LAGH) preparations in children. Three LAGH products have been approved in Europe and the United States for paediatric growth hormone deficiency (GHD): lonapegsomatropin,
Renata Stawerska
doaj +2 more sources
Long-acting growth hormones: innovations in treatment and guidance on patient selection in pediatric growth hormone deficiency [PDF]
Annals of Pediatric Endocrinology & MetabolismLong-acting growth hormones (LAGHs) represent a significant advancement in the treatment of pediatric GH deficiency, offering an alternative to daily recombinant human GH (rhGH) therapy.
Chiara Rodaro +3 more
doaj +2 more sources
First 100 patients receiving long-acting growth hormone therapy: real-world evaluation from INSIGHTS-GHT registry [PDF]
Orphanet Journal of Rare DiseasesThe development of long-acting growth hormone (LAGH) formulations offers a promising approach to reduce injection frequency and to improve adherence in growth hormone deficiency (GHD) treatment.
Joachim Woelfle +5 more
doaj +2 more sources
Patients with Growth-Related Disorders and Caregivers Prefer the Somapacitan Device to the Somatrogon Device: Results from a Randomized Crossover Study Assessing Device Preference and Ease of Use Following Simulated Injections [PDF]
Medical Devices: Evidence and ResearchShahid Akhtar,1 Birgitte Berg,2 Johan Medina,3 Maya Nicole Gonczi,4 Sophie Hamilton,5 Emily Hildebrand,4 Nicky Kelepouris,6 Jesper Skov Neergaard,7 Claus Sværke,8 Gitte Ter-Borch,2 Niklas Kahr Rasmussen3 1Devices & Digital Health, Novo Nordisk A/S ...
Akhtar S +10 more
doaj +2 more sources
Once-Weekly Somapacitan as an Alternative Management of Growth Hormone Deficiency in Prepubertal Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trial [PDF]
ChildrenGrowth hormone treatment has effectively restored normal growth in children with growth hormone deficiency (GHD); however, it poses challenges in compliance with a daily growth hormone injection regimen, leading to low adherence and persistence rates ...
Ghina Tsurayya +6 more
doaj +2 more sources
Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis [PDF]
Scientific ReportsThe purpose of this study is to compare the relative efficacy and safety of long-acting growth hormone (LAGH) as a growth hormone replacement therapy in prepubertal children with growth hormone deficiency (GHD).
Jianfang Zhu +6 more
doaj +2 more sources
Developments in the Management of Growth Hormone Deficiency: Clinical Utility of Somapacitan [PDF]
Drug Design, Development and TherapyBradley S Miller,1 Jo Blair,2 Reiko Horikawa,3 Agnès Linglart,4– 7 Kevin CJ Yuen8 1Division of Pediatric Endocrinology, University of Minnesota Medical School, MHealth Fairview Masonic Children’s Hospital, Minneapolis, MN, USA; 2Department of Paediatric ...
Miller BS +4 more
doaj +2 more sources